Investment, Funding & Disinvestments

The program will also work to increase access to chemotherapy and provide essential emotional support services for patients navigating their cancer journey.

The sale came about following an unsolicited offer from BGH Capital, which focuses on investments in Australia and New Zealand.

The deal collapsed after STAAR failed to secure sufficient shareholder approval during a special stockholders meeting held on January 6.

This approach will help ensure that the local manufacturing of diagnostic imaging equipment remains economically viable and financially sustainable over the coming years.

Amgen’s latest acquisition is centered on Dark Blue’s lead candidate, DBT 3757, which specifically treats acute myeloid leukemia that affects bone marrow and blood cells.

With a capacity exceeding 300 beds, the hospital will deliver both primary and secondary healthcare services to citizens and residents throughout the wilayat and surrounding areas.

Sanofi will leverage Earendil’s artificial intelligence (AI)-powered drug discovery platform to support the design and development of multiple new therapeutic assets.

Through this agreement, Sanofi will gain full ownership of Heplisav-B, a two-dose hepatitis B vaccine that received US approval in 2017 and European authorization in 2021.

ADU-CRI operates through five specialized research divisions that target critical aspects of cancer care: Genomics and Bioinformatics Research, Biomarker Research, Drug Discovery and Development, Biosensors and Bioengineering, and Public Health Research.

Through this acquisition, J&J gains access to HLD-0915, a clinical-stage, once-daily oral therapy intended for the treatment of prostate cancer.